Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05999513 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers
A Phase 1 study, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05999513 is a Phase 1 study that has completed, run by Arcus Biosciences. The registered enrollment target is 24 participants.
The verdict
NCT05999513, a Phase 1 study, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the single-dose pharmacokinetics (PK) of casdatifan tablet versus the casdatifan capsule, and to evaluate the effect of food on the single-dose PK of casdatifan tablet in healthy adult volunteers.
Interventions
- DRUG casdatifan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-08-21 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05999513
The ClinicalTrials.gov registry entry for NCT05999513 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which casdatifan is the first listed.
NCT05999513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05999513 about?
NCT05999513 is a clinical study titled "A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers". The primary purpose of this study is to compare the single-dose pharmacokinetics (PK) of casdatifan tablet versus the casdatifan capsule, and to evaluate the effect of food on the single-dose PK of casdatifan tablet in healthy adult volunteers.
What is the current status of trial NCT05999513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-08-21. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT05999513?
The interventions under investigation include: casdatifan (DRUG).
Who is sponsoring clinical trial NCT05999513?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.